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Abstract
The electrophysiological properties of acute and chronic methylphenidate (MPD) on neurons of the
prefrontal cortex (PFC) and caudate nucleus (CN) have not been studied in awake, freely behaving
animals. The present study was designed to investigate the dose-response effects of MPD on sensory
evoked potentials recorded from the PFC and CN in freely behaving rats previously implanted with
permanent electrodes, as well as their behavioral (locomotor) activities. On experimental day 1,
locomotor behavior of rats was recorded for 2 h post saline injection, and sensory evoked field
potentials were recorded before and after saline and 0.6, 2.5, and 10 mg/kg, i.p., MPD administration.
Animals were injected for the next five days with daily 2.5 mg/kg MPD to elicit behavioral
sensitization. Locomotor recording was resumed on experimental days 2 and 6 after the MPD
maintenance dose followed by three days of washout. On experimental day 10, rats were connected
again to the electrophysiological recording system and rechallenged with saline and the identical
MPD doses as on experimental day 1. On experimental day 11, rat’s locomotor recording was
resumed before and after 2.5 mg/kg MPD administration. Behavioral results showed that repeated
administration of MPD induced behavioral sensitization. Challenge doses (0.6, 2.5, and 10.0 mg/kg)
of MPD on experimental day 1 elicited dose-response attenuation in the response amplitude of the
average sensory evoked field potential components recorded from the PFC and CN. Chronic MPD
administration resulted in attenuation of the PFC’s baseline recorded on experimental day 10, while
the same treatment did not modulate the baseline recorded from the CN. Treatment of MPD on
experimental day 10 resulted in further decrease of the average sensory evoked response compared
to that obtained on experimental day 1. This observation of further decrease in the
electrophysiological responses after chronic administration of MPD suggests that the sensory evoked
responses on experimental day 10 represents neurophysiological sensitization. Moreover, two
different response patterns were obtained from PFC and CN following chronic methylphenidate
administration. In PFC, the baseline and effect of methylphenidate expressed electrophysiological
sensitization on experimental day 10, while recording from CN did not exhibit any
electrophysiological sensitization.
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1. INTRODUCTION
Psychostimulants were initially proposed for the treatment of attention deficit hyperactivity
disorder (ADHD) in 1937 and is currently used as the treatment of choice (Eichlseder
1985;Swanson et al., 1999;Challman and Lipsky, 2000). The psychostimulant methylphenidate
(MPD; ritalin) has become the most prescribed medication for ADHD (Solanto 1998;Challman
and Lipsky, 2000;Accardo and Blondis, 2001;Swanson and Volkow, 2002). It is estimated that
5–15% (2–6 million) of the U.S. population between 5 and 18 years old is being treated with
MPD (Anderson et al., 1987;Rowland et al., 2001;Barbaresi et al., 2002). Since ADHD persists
into adulthood, these individuals continue to take MPD well into their adulthood (Himelstein
and Halperin, 2000). Yet little is known of the long-term consequences of MPD (Musser et al.,
1998;MacDonald and Kollins, 2005;Kollins et al., 2001;Carlezon and Konradi,
2004;MacDonald and Kollins, 2005).
Behavioral experiments in animals using repeated exposure to psychostimulants demonstrated
that these drugs elicit behavioral sensitization. Behavioral sensitization refers to the progressive
augmentation of the initial, behavioral responses to a psychostimulant (Leith and Kuczenski,
1982;Kalivas and Stewart, 1991;Wolf 1998). A sensitized response to a psychostimulant is
elicited by the intermittent administration of a low dose of the psychostimulant, while higher
doses produce tolerance (Leith and Kuczenski, 1982;Robinson and Berridge, 1993).
Behavioral sensitization is believed to be an early manifestation of the neuronal plasticity
associated with repeated administration of a drug of abuse and may provide evidence for the
underlying alterations that resulted in craving as well as relapse that occurs after a period of
abstinence and play a central role in the development of addictive behavior (Robinson and
Berridge, 1993). Thus, behavioral sensitization can serve as an animal model to study drug
craving (Robinson and Berridge, 1993;Kalivas et al., 1998) and the induction of persistent
changes in the neuronal circuitry of motivation and reward following chronic exposure to
psychostimulants (NIHCDCS, 2000). Repeated administration of amphetamine, cocaine, and
methamphetamine has been shown to elicit behavioral sensitization (Robinson and Becker,
1986;Segal and Kuczenski, 1987;Pierce and Kalivas, 1997;Crawford et al., 1998). However,
findings of behavioral sensitization resulted from repeated exposure to MPD have been
inconsistent (McNamara et al., 1993;Gaytan et al., 1997a;Izenwasser et al., 1999;Kuczenski
and Segal, 2002;Yang et al., 2003).
Psychostimulants exert their effect mainly on the CNS. Therefore, it is important to study the
effects of the drug on the brain itself. Most of the investigators studying brain functions use
procedures to evoke brain related events. To obtain brain related events, they stimulate the
animal to evoke responses before and after treatments (Dafny and Feldman, 1970;Dafny
1975b;Dafny et al., 1975;Dafny 1975c,1998;Dafny and Gildenberg, 1984). One of the “best”
approaches to obtain events in the CNS is to use physiological sensory stimulation such as
acoustic. These stimulations do not require any surgical procedure or cause pain to the animals.
Any sensory information entering the CNS spreads to many brain areas (Dafny et al.,
1975;Dafny 1998). Each area processes this information for different functions. Moreover,
MPD exerts its effects by altering sensory inputs to the subject (Kaufmann et al.,
1984;Eichlseder 1985;Gittelman et al., 1985;Biederman et al., 1994;Laviola et al.,
1999;Swanson et al., 1999;Greenhill 2001). Therefore, it is essential to study the effect of
psychostimulants on sensory input.
Yang et al. Page 2
Brain Res. Author manuscript; available in PMC 2007 June 27.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
The “ideal” preparation to study the effects of drug on the CNS is in an unanesthetized, freely
behaving animals previously implanted with permanent electrodes and to use physiological
stimulation. The use of intact, freely behaving animals made it possible to study the underlying
neurophysiological mechanisms of acute and chronic MPD treatment at the cellular level (i.e.,
electrophysiology) and systems level (behavior) without interference of anesthesia. Therefore,
in the present study, unanesthetized, freely behaving animals previously implanted with
permanent electrodes (under anesthesia) and sensory stimulation will be used to investigate
the effects of acute and chronic MPD on behavior and electrophysiology from the same
animals.
Patients diagnosed with ADHD exhibit dopaminergic and noradrenergic abnormalities/
dysfunction in the prefrontal cortex (PFC) and caudate nucleus (CN) (Arnsten et al.,
1996;Sergeant et al., 2002;Seidman et al., 2004;Bush et al., 2005). Yet little is known about
the mechanisms contributing to MPD’s therapeutic efficacy or the possible enduring
neuroadaptational consequences of long-term drug exposure at these sites (National Institutes
of Health Consensus Development Conference Statement, 2000;Greenhill, 2001). Specifically,
there is lack of data demonstrating, in freely behaving rats, the neurophysiological outcome
from acute and chronic treatment of MPD on sensory evoked potentials. Because the main site
of MPD action is the CNS, it is essential to study the effect of MPD on the brain regions
suggested to be the CNS sites for psychostimulant action and whether sensory information and
processing in these regions are influenced by the acute and chronic exposure to MPD.
Therefore, the present study set out to investigate the effect of MPD on sensory input at the
PFC and CN sites known to be the targets for psychostimulants in awake, freely behaving rats
previously implanted with permanent electrodes.
2. RESULTS
2.1. Locomotor behavior
Controls – Locomotor activity of eight rats were recorded continuously (24 h) for 42 days
without any treatment. Locomotor activity count was collected for each 10-min samples (bin
at 10 min) and summed into light (12 h), dark (12 h), daily (24 h), and weekly locomotor activity
in order to determine whether the locomotor activity would change over time without treatment.
Figure 1 summarizes the horizontal activity of this experiment and demonstrates that the
locomotor activity during the 42 days without treatment remained essentially the same with
minor fluctuations during the 12 h light period (Fig. 1A), 12 h night period (Fig. 1B), or 24 h
during the light and dark cycle, and weekly activity for six weeks (Fig. 1D), respectively. Figure
2 summarizes the horizontal and vertical activities of ten rats that were implanted with
electrodes in the PFC and CN and had received saline and repeated MPD administration (see
Table 1). These animals were also used in the electrophysiological experiment. Values are
presented as the mean + S.E.M. with * P < 0.05. The bar graphs summarize the 2-h cumulative
horizontal and vertical activities under the temporal curve of experimental days 1, 2, 6, and
11. An injection of 2.5 mg/kg MPD on experimental day 2 exhibited similar activity level as
that of baseline on experimental day 1. However, after five days of repeated 2.5 mg/kg MPD
administration, both the horizontal and vertical activities on experimental day 6 were
significantly augmented compared to day 2 [F 3,39 = 4.31, *P = 0.021 (horizontal); F 3,39 =
3.72, *P = 0.046 (vertical)]. This augmentation persisted on experimental day 11 compared to
day 2 (*P < 0.05). This augmentation demonstrated that the chronic MPD administration of
2.5 mg/kg MPD elicited behavioral sensitization.
2.2. Sensory evoked field responses
Controls – Three electrophysiological control recordings were obtained. Figure 3A shows a
representative of the average acoustic evoked responses (AAER) recording from the CN
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beginning 1 h after the animals were connected to the electrophysiological recording system,
and recordings were obtained every 30 min. The data showed that the AAER remained stable
over time if no treatment was given. Figure 3B shows four consecutive AAER recording every
10 min (control) and an additional four AAER recorded following two consecutive saline
injections (middle and right columns). Time between injections was 120 min. This recording
demonstrated that handling of the animal (i.e., inserting the needle into the animal and injection
volume) did not modulate the AAER. Figure 3C shows simultaneous recordings of AAER
from CN and PFC. Each column shows four consecutive AAER recordings every 10 min post-
saline injection throughout 4 consecutive weeks from the same animals. This figure indicates
that the AAER over long period of time (4 weeks) remained stable and expressed similar
response amplitudes. Therefore, every significant deviation from baseline indicated the effect
of the drug.
Figure 4 shows representatives AAER recorded simultaneously in the PFC and CN following
the administration of saline (baseline) and a single injection of 0.6, 2.5, and 10.0 mg/kg, i.p.,
MPD on experimental day 1. All three MPD doses attenuated significantly (P < 0.05) the
amplitude response of the AAER components (P2, N2, and P3) as compared to their baseline
in both brain sites. Furthermore, this attenuation exhibited dose-response characteristics, i.e.,
further attenuation in the AAER amplitude was observed with increased MPD dosage.
Figure 5 summarizes the percent attenuation from baseline of the AAER amplitude for P2, N2,
and P3 components recorded from the PFC and CN following 0.6, 2.5, and 10.0 mg/kg MPD,
i.p., on experimental day 1. The control amplitude after saline administration (baseline) was
arbitrarily set as 100%. Each component’s percent attenuation from baseline following MPD
administration was calculated as the average of four post-injection time points recorded (10,
20, 30, and 40 min post-injection) and is presented as the mean ± S.E.M. Figure 5A shows that
an injection of 0.6, 2.5, and 10.0 mg/kg MPD, in general, significantly decreased the PFC’s
AAER amplitude of P2 [F3,15= 23.86, ΔP < 0.01], N2 [F3,15= 77.16, ΔP < 0.01], and P3
[F3,15= 91.33, ΔP < 0.01] components compared to those of baseline. Additionally, each of
these AAER components was attenuated differently in dose-response characteristics with N2
and P3 components exhibiting greater percent attenuation from baseline than P2 component
[0.6 mg/kg (F2,11= 39.96, *P < 0.01); 2.5 mg/kg (F2,11= 12.92, *P < 0.01); and 10.0 mg/kg
(F2,11= 7.75, *P < 0.05)]. Similar to PFC, an acute administration of 0.6, 2.5, and 10.0 mg/kg
MPD also significantly reduced the CN’s AAER amplitude of P2 [F3,15= 39.06, ΔP < 0.01],
N2 [F3,15= 127.96, ΔP < 0.01], and P3 [F3,15= 41.32, ΔP < 0.01] components compared to
those of baseline (Fig. 5B). When similar comparison for the effect of escalating doses of MPD
was performed, it was observed that the three doses of MPD also attenuated the CN’s AAER
amplitude of these components in dose-response characteristics. However, there was no
significant difference in the level of attenuation among the three peak components at each MPD
dose as observed in the PFC, i.e., all three components for each MPD dose were similarly
affected.
Figure 6A shows representatives AAER recorded simultaneously in the PFC and CN after the
administration of saline (baseline) on experimental days 1 and 10. In general, six days of
repeated MPD administration followed by three days of washout significantly reduced the
baseline of the AAER amplitude of the N2 and P3 components on experimental day 10
compared to that of day 1 in the PFC, while the baseline recording from the CN at experimental
day 10 remained similar to that of experimental day 1. Figure 6B summarizes the data for all
recordings and compares the percent change of the AAER amplitude of P2, N2, and P3 recorded
simultaneously in the PFC and CN on day 10 to that of day 1. The response amplitude after
saline administration on experimental day 1 was arbitrarily set as 100%. There was significant
attenuation of AAER baseline on day 10 compared to day 1 for N2 and P3 components of the
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PFC [N2: F1,13= 4.76, *P = 0.05; P3: F1,13= 13.86, *P = 0.003] but not for the AAER
components of the CN.
Figure 7 shows representatives of AAER recorded simultaneously in the PFC and CN of a rat
following the administration of saline (baseline) and 0.6, 2.5, and 10.0 mg/kg MPD on
experimental days 1 and 10. The figure shows the control recording and the effect of drug 20
min post-injection and demonstrates that, on experimental day 1, the recording of AAER from
MPD-naïve animal following each incremental MPD injection elicited further attenuation of
all the AAER components recorded from the PFC and CN as compared to control recording
and to the previous MPD dose. The recording on experimental day 10 was performed after
chronic MPD administration (see Table 1) when the animals became behaviorally sensitized
to MPD (Fig. 2). The baseline recording on experimental day 10 exhibited differences in AAER
recordings between PFC and CN. The baseline AAER obtained from the PFC on experimental
day 10 was attenuated for all the response components as compared to the control on
experimental day 1; whereas the baseline control recorded from the CN on experimental days
1 and 10 was similar. In a comparison of all recordings of the control AAER components from
the PFC on experimental day 10 with those of experimental day 1, significant (P < 0.05)
attenuation was observed. Moreover, when incremental MPD doses were given on
experimental day 10 (i.e., in MPD behaviorally sensitized animals), each MPD dose (0.6, 2.5,
and 10.0 mg/kg) elicited further attenuation of all AAER components (Fig. 7 – PFC: day 10).
Such further attenuation could represent electrophysiological sensitization to MPD in the PFC.
The AAER recording from the CN exhibited different characteristics on experimental day 10.
The CN’s control AAER on experimental day 10 was the same as that obtained on experimental
day 1. The level of AAER attenuation following incremental MPD treatment on experimental
day 10 was also similar to that on experimental day 1 in MPD-naïve animals. This observation
indicates that electrophysiological sensitization to MPD was not expressed in the CN.
3. DISCUSSION
In the present study, we investigated neurophysiologically the dose-response characteristics of
MPD in MPD-naïve animals (experimental day 1) and when these same animals became
behaviorally sensitized to MPD (experimental day 10). We accomplished this by recording the
MPD effects on AAER obtained simultaneously in the PFC and CN of non-anesthetized, freely
behaving rats previously implanted with permanent electrodes, as well as recording the
locomotor activity before and after repeated administration of this psychostimulant to verify
that the drug treatment elicits behavioral sensitization. Indeed, all of the experimental animals
exhibited behavioral sensitization to the MPD treatment (Fig. 2).
In the behavioral experiment, we found that repeated administration of saline did not have any
effect on locomotion, while repeated administration of MPD induced behavioral sensitization
as indicated by the progressive augmentation of the horizontal and vertical activities (Fig. 2)
on experimental days 6 and 11 compared to experimental day 2. The horizontal and vertical
activities on experimental day 2 following 2.5 mg/kg MPD administration were similar to that
of saline on experimental day 1. However, after five consecutive days of a daily injection of
the maintenance dose of 2.5 mg/kg MPD, the horizontal and vertical activities of the rats
increased significantly on experimental day 6 compared to that of day 2. This increase in
locomotor response persisted on experimental day 11. These results are in accordance with
previous studies that had demonstrated the development of behavioral sensitization following
repeated administration of MPD (Gaytan et al., 1997a;Crawford et al., 1998;Kuczenski and
Segal, 2001;Yang et al., 2003). However, other investigators had reported that chronic
exposure to MPD in rats failed to induce behavioral sensitization (McNamara et al.,
1993;Izenwasser et al., 1999;Kuczenski and Segal, 2002). A possible explanation for these
inconsistent findings is methodological variations. Specifically, factors such as dose, route,
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time, regimen of drug administration, and the locomotor indices recorded can critically affect
the observation to show whether behavioral sensitization was developed (Robinson and
Becker, 1986;Gaytan et al., 1997a;White and Kalivas, 1998;Kuczenski and Segal, 2001,
2002;Dafny and Yang, 2006).
The present study investigated the effect of MPD on sensory input recorded simultaneously
from the PFC and CN. Sensory evoked field potential is an electrophysiological measure often
used for analyzing information processing in the brain (Picton et al., 2000). A major advantage
of using this electrophysiological technique is that it provides both an average sampling of
evoked activity in a neuronal population (Dafny et al., 1975;Dafny 1975a,1978) and the means
to study sensory input and processing in millisecond temporal resolution time locked to the
stimulus occurrence (Winsberg et al., 1997).
The amplitude of the sensory responses consists of P1, N1, P2, N2, and P3 components.
Although the cognitive processes and their underlying mechanisms associated with these
components have not been definitely established, it is believed that P1 and N1 components
represent the presynaptic incoming impulses, while P2, N2, and P3 components reflect the
postsynaptic activity within the recording site (Dafny et al., 1975;Dafny 1978). Moreover, it
has been suggested that the P2 represents the beginning of a central process responsible for
stimulus identification and the initiation of decision, while N2 and P3 represent the end of this
process (Lindholm and Koriath, 1985). The P3 component is suggested to also indicate further
processing and evaluation of the relevant stimuli, such as stimulus categorization (Teo and
Ferguson, 1986). A reduction of P3 amplitude implies cognitive dysfunction (Michie et al.,
1990;Solowij et al., 1991).
The electrophysiological experiment revealed that MPD treatment in MPD-naïve rats
(experimental day 1) attenuated the AAER’s recorded from the PFC and CN in dose-response
characteristics, i.e., each incremental MPD dose caused further decrease in the AAER.
Moreover, similar doses of MPD in MPD behaviorally sensitized animals (experimental day
10) further attenuated the AAER while the locomotor activity increased. These
electrophysiological findings suggest that the further decreases in the AAER expressed
neurophysiological sensitization in the PFC following the chronic treatment of 2.5 mg/kg MPD,
while this MPD dose did not elicit neurophysiological sensitization in the CN. Moreover,
chronic treatment of MPD attenuated the AAER baseline recording from the PFC on
experimental day 10, while the AAER recording from the CN remained the same on both
experimental days (1 and 10).
The electrophysiological findings from the present study suggest that there are differences in
the neuronal response to MPD between the PFC and CN. Functionally, the CN plays a key role
in motor activity and in the processing of sequential information (Aldridge and Berridge
1998;Nakamura et al., 2001), while the PFC has been implicated in the regulation of cognition
and emotion in rats, monkeys, and humans (Mazei et al., 2002), as well as in nearly every major
mental disorder in humans (Mazei et al., 2002). In particular, the PFC is thought to support
vigilance, selective and divided attention, attention shifting, planning, executive control,
working memory, and behavioral inhibition (Rubia et al., 1999; Duncan and Owen, 2002; Aron
et al., 2003). The mesocortical dopaminergic projection, which originates in the ventral
tegmental area (Emson and Koob, 1978), ascends to the PFC and has an important role in stress,
drug abuse, and schizophrenia (Goeders and Smith, 1983;Weinberger 1987;Abercrombie et
al., 1989), while the CN receives mainly DA projections from the substantia nigra.
In addition to anatomical and functional differences between the PFC and CN, there are
differences in the effects of MPD in the dopamine transporter (DAT) densities and rates of
dopamine (DA) release and uptake between these two brain regions, as well as blockade of the
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norepinephrine transporter (NET) (Carboni et al., 1990). Synaptic DA levels are regulated by
DAT, which is a critical protein for DA regulation since it is responsible for the reuptake of
DA from the synapse. The DAT is expressed in both the PFC and CN; however, its distribution
is not homogenous. The DAT content in the PFC is found to be lower than that of the CN
(Mazei et al., 2002). The rate of DA release and uptake in the PFC is about 8 times less than
that in the CN (Garris and Wightman, 1994). Moreover, it has been reported that blockade of
the norepinephrine transporter (NET) increases extracellular DA levels in the PFC, implying
that NET is also involved in clearing DA in the PFC of the rat (Carboni et al., 1990;Pozzi et
al., 1994; Gresh et al., 1995). The ability of NET to clear DA is significant since there is an
increased innervation of NE terminals compared to DA terminals in the PFC (Slopsema et al.,
1982). These differences in DAT and NET densities and rates of DA reuptake between PFC
and CN may account for the differences in their response to MPD as observed by the effects
of MPD on AAER.
Studies have demonstrated that psychostimulants induce changes in the release characteristics
of DA (Robinson et al., 1988;Kalivas and Duffy, 1990;Vezina 1993) and/or alterations in DA-
stimulated signal transduction mechanisms (Steketee et al., 1991;Steketee 1994;Miserendino
and Nestler, 1995), and these changes play a crucial role in the drug effect on locomotor and
neurophysiological sensitization. We posit that the increase in extracellular DA resulted from
MPD administration could activate postsynaptic DA receptors in motor nuclei and thereby
enhance the motor-activating effects. As the rat was repeatedly exposed to MPD, more
extracellular DA became available at the synaptic cleft and activated a greater number of
postsynaptic DA receptors. This activation of the motor nuclei could result in behavioral
sensitization. In contrast, activation of the presynaptic DA autoreceptors has been found to
exert a strong inhibitory effect on the neuronal activity (Ruskin et al., 2001) and thereby result
in the inhibition of the firing of DA neurons in the CNS (Bunney et al., 1973;Einhorn et al.,
1988;Shi et al., 2000,2004). This inhibitory role attenuated the sensory information arriving at
these sites, which may explain the result in attenuation of all three AAER components recorded
from the PFC and CN. Using amphetamine and in vivo microdialysis, it was reported that other
neurotransmitters and/or mechanism could contribute to the chronic effect of the
psychostimulants (Segal and Kuczenski, 1992).
In conclusion, this is the first study that investigated, in the same freely moving subjects, the
animal behavior at the systems level and the sensory evoked field potentials at the neuronal
level of the PFC and CN. This study provides the dose-response characteristics of acute and
chronic MPD administration recorded from freely behaving animals implanted with permanent
electrodes and suggests that chronic MPD elicited plasticity in the PFC, as well as
neurophysiological sensitization to MPD, while MPD exerted different effects in the CN. It is
clear from the data that further investigations into the sensory evoked field responses at the
neuronal level are warranted in the elucidation of the mechanisms of drug action of MPD and
its long-term effects on the CNS.
4. MATERIALS AND METHODS
4.1. Subjects
Twenty six male Wistar-Kyoto rats (WKY) were used in the experiment. Eight animals were
used for behavioral time control experiment (Fig. 1), eight for electrophysiological experiment
to obtain the average acoustic evoked responses (AAER) over time (Fig. 3A), following animal
handling (Fig. 3B) and recording over several weeks (Fig. 3C), and ten for the acute and chronic
dose response effects of MPD on AAER. The animals weighed 180–190 g at arrival from the
vendor (Harlan Laboratories, Indianapolis, IN, USA). They were housed 2 per Plexiglas cage
and maintained at an ambient temperature of 21 ± 2 °C and a relative humidity of 37–42% in
the vivarium on a 12-h light/dark cycle (lights on from 05:30 to 17:30 h). The animals were
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allowed 3–7 days of acclimation to this environment before commencement of any
experimental manipulation. They received food and water ad libitum throughout
experimentation. All experiments were performed in accordance with the National Institutes
of Health Guide for the Care and Use of Laboratory Animals, as well as our institution’s Animal
Welfare Committee Guidelines.
4.2. Drug
Methylphenidate hydrochloride (MPD) was supplied by Mallinckrodt, Inc. (St. Louis, MO,
USA). The drug was dissolved in 0.9% saline, and the dosages were calculated as free-base.
All injections were administered intraperitoneally (i.p.) between 07:00 h and 12:00 h and
equalized to a volume of 0.8 ml with 0.9% saline so that the total volume of each injection
would be the same for all animals. Time between injections was 120 min.
4.3. Surgical procedure
Rats were anesthetized with 50.0 mg/kg pentobarbital and fitted to a stereotaxic apparatus. An
incision of 2.0 cm was made to expose the skull. One millimeter holes were drilled through
the skull above the target sites to insert electrodes (stainless steel 80 μm in diameter) bilaterally
(in both hemispheres) at the PFC (Bregma 2.7 mm, lateral 0.6 mm, depth 3.8 mm) and CN
(Bregma 0.2 mm, lateral 3.2 mm, depth 4.4 mm) using coordinates derived from the Paxinos
and Watson (1986) atlas. An additional electrode was implanted in the frontal sinus as a
reference electrode. All electrodes were fixed permanently to the rat’s skull with dental acrylic
cement and attached to terminals in an Amphenol plug.
4.4. Experimental Design
Each rat participated in both behavioral and electrophysiological recordings (Table 1). On
experimental day 1 upon 5–7 recovery days from the surgical implantation of electrodes, the
rat was put inside the computerized, automated locomotor activity monitoring cage where its
behavioral baseline activity was recorded for 2 h after saline administration (Gaytan et al.,
1997a;Yang et al., 2003). It was then transferred to the electrophysiological test chamber where
its sensory evoked field potentials were recorded in response to acoustic stimulation following
the administration of saline and escalating doses of 0.6, 2.5, and 10.0 mg/kg MPD. On
experimental day 2, the rat was placed back inside the locomotor activity open field monitoring
cage and its behavioral activity recording was resumed for 2 h after 2.5 mg/kg MPD
administration (see Table 1). On experimental days 3 to 6, animals were treated with 2.5 mg/
kg MPD, which was the maintenance dose to elicit behavioral sensitization (Gaytan et al., 1997
a,b;Yang et al., 2003). Drug administration always occurred in the testing cage and not in the
home cage. Behavioral activity resumed on experimental day 6 following the last maintenance
of 2.5 mg/kg MPD. Washout period occurred on experimental days 7 to 9 in which the rats did
not receive any treatment. Experimental day 10 was identical as experimental day 1. Behavioral
testing of the rat resumed again on experimental day 11 after the administration of 2.5 mg/kg
MPD (see Table 1) to observe whether the animals expressed behavioral sensitization.
4.5. Behavioral apparatus
The computerized, automated, open field activity monitoring cage (Accuscan, Columbus, OH,
USA) consisted of a clear, acrylic box (40.5 × 40.5 ×31.5 cm) fitted with two levels of infrared
motion sensors located 6.0 and 12.5 cm above the floor of the box. The apparatus recorded
interruptions of each infrared beam at a frequency of 100 Hz. Interruptions of any infrared
beam were recorded as an activity score. Simultaneous interruptions of two or more consecutive
beams separated by at least 1 sec were recorded as a movement. Cumulative counts were
compiled and downloaded every 10 min into the OASIS data collection software (Accuscan)
that organized and differentiated these counts into various locomotor indices. Horizontal and
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vertical activities were the locomotor indices evaluated in the present study. Horizontal activity
measured the total number of beam interruptions that occurred in the horizontal sensor (lowest
tier), while vertical activity measured the amount of rearing (upper tier sensor) during a given
sample period.
4.6. Behavioral testing
Control—After 3–4 days of adaptation to the experimental room, each rat was placed in the
open-field testing cage for 42 days. This cage becomes the animal’s home cage. Once a day at
07:00 h, each cage was cleaned and water and food were given after which locomotor activity
resumed, i.e., continuous recording for 42 days. Data was evaluated for 42 days of daylight
activities, 42 nights of dark activities, and 42 24-h day and night together and weekly activities.
MPD experiment—On every testing day (see Table 1), each rat was placed in an open-field
cage and habituated for 15 to 20 minutes, after which saline/MPD injection was administered
and subsequent locomotor activity was recorded for 120 minutes. On experimental day 1 (see
Table 1), all animals were injected with saline prior to recording activity. On experimental
days 2, 6, and 11, locomotor activity was obtained following injection of 2.5 mg/kg MPD.
4.7. Analysis of behavioral data
The behavioral activity following saline administration on experimental day 1 served as the
control baseline activity. Previous studies showed that the duration of MPD effects on the rat’s
locomotor activity was approximately 50–80 min, depending on the MPD dose (Gaytan et al.,
1997a;Yang et al., 2003); therefore, cumulative locomotor activity was recorded for 120 min
after each saline/MPD treatment. Observations within a treatment group and between treatment
groups were analyzed using Analysis of Variance (ANOVA: experimental days and treatment).
Any statistical significance was determined with the post-hoc Fischer’s LSD method. The
statistical significance was set at P < 0.05 for all comparisons.
4.8. Sensory evoked field potentials recording
Three days before commencement of the experiment, rats were transferred to the
electrophysiological testing cage connected to the electrophysiological system via a
commutator for habituation to the electrophysiological experiment. Fifty acoustic click stimuli
were given and repeated every 10 min for 2 h on each of the three adaptation days. On
experimental day 1 after the behavioral recording, the rats were transferred to a cubic Plexiglas
box (23 cm3) located inside a sound-insulated, electrophysiological test chamber and connected
to the electrophysiological system for acclimation to the electrophysiologically testing
conditions.
Animal was allowed to habituate for 30 to 40 min before commencement of the experiment.
The electrodes in the rat’s head were connected to a Grass P511 amplifier through the emitter
follower by means of low noise leads to a commutator mounted on a counterbalanced arm that
allowed the rat to move about freely in the Plexiglas box. The amplifier output was connected
to the Micro 1041 (Cambridge Electronic Design, Cambridge, UK) for data collection and to
multi-beam oscilloscopes to monitor neuronal activities. The Micro 1041 was connected to a
PC computer equipped with the Spike 2 software (Cambridge Electronic Design) for digitizing,
averaging, and storing the data in the hard drive for off-line evaluation. Acoustic stimulation
was in the form of ‘clicks’ produced by a Grass AC-5 ultralinear, audio-stimulator connected
to a remote speaker (10.0 cm in diameter), which was placed 1 cm in front of the Plexiglas box
and triggered by a 4–5 volt square pulse of 0.1 ms in duration. Measuring the intensity of the
click stimulus in the Plexiglas before the experiment was from peak to peak amplitude of 80
DB SPL (re 0.0002 dyne/cm2). A digitimer device (Medical System #3290) triggered the
acoustic stimulator and all other electronic equipments. Fifty consecutive click stimuli, each
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at every 2.4 second, was presented (1 set) and used to produce one average. Four such sets
were presented at 10-min intervals after each treatment (saline, 0.6, 2.5, and 10.0 mg/kg MPD,
respectively). These four averages, each of 50 stimuli, were averaged to produce final
amplitude for comparison between the control and the different drug doses (see Fig. 3B and
3C). Each stimulating session lasted 2 min (50 stimuli every 2.4 sec = 120 sec = 2 min), i.e.,
time interval between each set was 10 min.
4.9. Histological verification of electrode placement
At the conclusion of the experiments, the rats were overdosed with sodium pentobarbital. A
lesion was produced at the tip of each of the electrodes by passing a 50 μA direct current for
30 sec. The rats’ brain was transcardially perfused with a 10% formalin solution containing
3% potassium ferrocyanide. Brain slices were cut serially at a thickness of 80–100μ using a
vibrotome (OTS-3000-03; FHC, Brunswick, ME, USA) and histologically stained with Cresyl
violet. The position of the electrode tips were identified by the location of the lesion and the
Prussian blue spot. After histological verification, it was found that only 7 electrodes were
located within the PFC and 19 electrodes within the CN. Recordings from these verified PFC
and CN location were analyzed and presented.
4.10. Electrophysiological data analysis
Fifty sensory evoked responses (1 set) were averaged off-line using the Spike 2 software
(Cambridge Electronic Design, Cambridge, UK). Four sets of recordings, each following
saline, 0.6, 2.5, and 10.0 mg/kg MPD, were obtained. Each average of acoustic evoked
responses (AAER) was evaluated in terms of amplitude (μv) of the characteristic components.
Amplitudes were measured from peak to peak. The AAER of a rat consisted of five main
amplitude/components: P1, N1, P2, N2, and P3 (Dafny 1975a,1978;Dafny et al., 1981;Yang
et al., 2006). The ‘P’ indicates positive amplitude, while the ‘N’ indicates negative amplitude.
The integers indicate the first, second, or third positive or negative component. That is, P1
refers to the first positive component of the evoked field response amplitude. The P1 and N1
components were not consistent within and between rats and therefore were not evaluated. The
P2, N2, and P3 components were the most consistent components within and between rats and
therefore were analyzed.
Changes induced by each of the three doses of MPD were analyzed by comparing the control
amplitude of each component averaged (e.g., P2) to that obtained following drug injection
recording. Results were analyzed by repeated measures ANOVA with the post-hoc Fischer’s
LSD method for treatment, day, and brain site comparisons. A significant level of 0.05 was
applied throughout all analyses. Each animal served as its own control.
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Figure 1.
A–C summarizes the 24 h horizontal activity (upper histogram) and the 12 h night time (dark)
activity (middle histogram) and the 12 h daytime activity (lower histogram). Figure 1D
summarizes the total activity/week (N = 8). This figure demonstrates that the locomotor activity
during the 42 days remained essentially the same with minor fluctuations.
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Figure 2.
summarizes the horizontal and vertical activities (n = 10) that had received saline and repeated
MPD administration. Values are presented as the mean + S.E.M. with * P < 0.05. The bar
graphs summarize the 2-h cumulative horizontal and vertical activities on experimental days
1, 2, 6, and 11.
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Figure 3.
shows that the average acoustic evoked responses (AAER; n = 50) during the experiment (time
control) remained the same if no treatment was given, and saline injection did not alter the
AAER. Figure 3A shows a representative recording from the CN beginning 1 h after the animal
was connected to the electrophysiological recording system, and recordings were obtained
every 30 min. Figure 3B shows four consecutive recording every 15 min (control) before and
after two saline injections. The number indicates the recording time (min) post-saline injection
and shows that animal handling during injection did not alter the AAER. Figure 3C shows
simultaneous recordings from CN and PFC. Each column shows four consecutive recordings
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every 10 min post-saline injection throughout 4 consecutive weeks from the same animals and
that the AAER over time did not change.
Yang et al. Page 19
Brain Res. Author manuscript; available in PMC 2007 June 27.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4.
shows representatives of the averaged (n = 50) acoustic evoked responses (AAER) recorded
simultaneously in the PFC and CN following the administration of saline (baseline) and a single
injection of 0.6, 2.5, and 10.0 mg/kg, i.p., MPD on experimental day 1. Recordings were
obtained between 10 and 40 min post-injection of saline and MPD.
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Figure 5.
summarizes the percent attenuation from baseline of the AAER amplitude for P2, N2, and P3
components recorded from the PFC (Fig. 5A; n = 7) and CN (Fig. 5B; n = 19) following 0.6,
2.5, and 10.0 mg/kg MPD, i.p., on experimental day 1. The control amplitude after saline
administration (baseline) was arbitrarily set as 100%. Each component’s percent attenuation
from baseline following MPD administration was calculated as the average of four post-
injection time points (10, 20, 30, and 40 min) and is presented as the mean ± S.E.M. ΔP < 0.05
compared to baseline at 100%; *P < 0.05 compared to P2 component.
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Figure 6.
A shows representatives of the AAER recorded simultaneously in the PFC and CN after the
administration of saline (baseline) on experimental days 1 and 10. Figure 6B summarizes the
data for all recordings and compares the percent change of the AAER amplitude of P2, N2,
and P3 recorded simultaneously in the PFC (n = 7) and CN (n = 19) on day 10 to that of day
1. The amplitude after saline administration on experimental day 1 was arbitrarily set as 100%.
All recordings were obtained between 10 and 40 min following saline injection. *P < 0.05
compared to day 1 baseline at 100%.
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Figure 7.
shows representatives of AAER (n = 50) recorded simultaneously in the PFC and CN of a rat
following the administration of saline (baseline) and 0.6, 2.5, and 10.0 mg/kg MPD on
experimental days 1 and 10.
Yang et al. Page 23
Brain Res. Author manuscript; available in PMC 2007 June 27.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Yang et al. Page 24
Table 1
Experimental protocol
Exp’l Day 1 2 3–5 6 7–9 10 11
Treatment Saline – B
Saline – E
0.6* – E
2.5* – E
10.0* – E
2.5– B* 2.5 – M* 2.5 – B* Washout Saline – E
0.6* – E
2.5* – E
10.0* – E
2.5 – B*
*
= mg/kg MPD B = Behavioral recording E = Electrophysiological recording M = Maintenance dose
On experimental day 1, behavioral recording (B) was performed for 2 h after saline injection. The rat was then placed in the electrophysiological testing
chamber where electrophysiological recordings were performed after saline (baseline) and 0.6, 2.5, and 10.0 mg/kg MPD administration. On experimental
day 2, behavioral testing (2 h) was carried out after 2.5 mg/kg MPD injection. Maintenance (M) dose of 2.5 mg/kg MPD was given on days 3–5 without
any recording. Behavioral testing (2 h) occurred after 2.5 mg/kg MPD injection on day 6. Days 7–9 were washout days (drug abstinence).
Electrophysiological recordings resumed on day 10 after saline (baseline) and 0.6, 2.5, and 10.0 mg/kg MPD. On experimental day 11, behavioral testing
resumed after 2.5 mg/kg MPD. Time between injections on experimental days 1 and 10 was 120 min.
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